دواعي استعمال ريميرون 30مجم 10 اقراص

Mirtazapine 30 mg film-coated tablets (Remeron, Organon), pack of 10 tablets, marketed in Egypt.

• Major depressive disorder in adultsDailyMed (U.S. National Library of Medicine)

• Most common (>=5% and twice placebo) in MDD trials: somnolence, increased appetite, weight gain and dizziness.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Use with, or within 14 days of stopping, MAOIs (including linezolid or intravenous methylene blue) because of serotonin syndrome risk.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to mirtazapine or any excipient.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Boxed warning: antidepressants increased suicidal thoughts and behaviours in pediatric and young adult patients; monitor all patients for clinical worsening; not approved in pediatric patients.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Agranulocytosis, serotonin syndrome, angle-closure glaucoma, QT prolongation, DRESS and other severe skin reactions, increased appetite/weight gain, somnolence, mania activation, seizures, raised lipids, hyponatraemia and discontinuation syndrome.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• MAO inhibitorsContraindicated: increased risk of serotonin syndrome.DailyMed (U.S. National Library of Medicine)
• Other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol etc.)Increased serotonin syndrome risk; monitor.DailyMed (U.S. National Library of Medicine)

• Published observational data and postmarketing reports have not reliably identified a drug-associated risk of major birth defects, miscarriage or adverse outcomes; untreated depression carries risks.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)
• Mirtazapine is present in human milk at low levels (relative infant dose about 0.6-2.8%); no adverse effects reported in most breastfed infants.نشرة دولية لنفس المنتج · DailyMed (U.S. National Library of Medicine)

• Antagonism of central alpha2-adrenergic, 5-HT2 and 5-HT3 receptors enhancing noradrenergic and serotonergic activity (per directory pharmacology note).